Stay updated with breaking news from Phase 2 Augment 101 Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 2 data from the AUGMENT-101 study show that revumenib elicits responses with acceptable safety in pediatric patients with KMT2A+ acute leukemia.
Revumenib demonstrated clinically meaningful activity, including high response and minimal residual disease negativity rates, in heavily pretreated patients with KMT2A-rearranged acute leukemia.